Genelux Corporation (GNLX)
- Previous Close
2.6200 - Open
2.7000 - Bid 2.0100 x 200
- Ask 3.3100 x 200
- Day's Range
2.5550 - 2.8500 - 52 Week Range
2.5000 - 40.9800 - Volume
891,986 - Avg. Volume
188,178 - Market Cap (intraday)
75.321M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.00
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
www.genelux.comRecent News: GNLX
Performance Overview: GNLX
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNLX
Valuation Measures
Market Cap
70.73M
Enterprise Value
53.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.60k
Price/Book (mrq)
4.69
Enterprise Value/Revenue
6.68k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-82.14%
Return on Equity (ttm)
-290.10%
Revenue (ttm)
8k
Net Income Avi to Common (ttm)
-25.78M
Diluted EPS (ttm)
-0.9200
Balance Sheet and Cash Flow
Total Cash (mrq)
19.63M
Total Debt/Equity (mrq)
15.72%
Levered Free Cash Flow (ttm)
-11.13M